KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Gross Margin (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Gross Margin data on record, last reported at 12.66% in Q3 2025.

  • For Q3 2025, Gross Margin fell 4169.0% year-over-year to 12.66%; the TTM value through Sep 2025 reached 25.09%, down 3119.0%, while the annual FY2024 figure was 57.28%, 525.0% down from the prior year.
  • Gross Margin reached 12.66% in Q3 2025 per NKTR's latest filing, down from 100.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q2 2025 and bottomed at 65.01% in Q1 2025.
  • Average Gross Margin over 5 years is 57.66%, with a median of 69.51% recorded in 2023.
  • The widest YoY moves for Gross Margin: up 4778bps in 2025, down -11323bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 75.36% in 2021, then dropped by -5bps to 71.7% in 2022, then decreased by -3bps to 69.51% in 2023, then crashed by -51bps to 33.72% in 2024, then plummeted by -62bps to 12.66% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 12.66% in Q3 2025, 100.0% in Q2 2025, and 65.01% in Q1 2025.